Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder

Sampath, Harshavardhan; Sharma, Indira; Dutta, Sanjiba

doi:10.1111/appy.12220

Cited by 11 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ketamine is a medication mainly used for starting and maintaining anesthesia, but recently, new insights have been gained into its potential antidepressive effects. As an N -methyl- d -aspartate receptor antagonist, effects of ketamine on mood disorders have been studied in many clinical studies 18,19. A systematic review reported that ketamine might be used as a valid and intriguing antidepressant option for treatment-resistant depression (TRD) 20.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Han

Chen

Zou

et al. 2016

NDT

View full text Add to dashboard Cite

BackgroundAn increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD.MethodRandomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted.ResultsNine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger’s test showed no publication bias.ConclusionThese results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Han

Chen

Zou

et al. 2016

NDT

View full text Add to dashboard Cite

show abstract

“…As noted at the beginning pharmacotherapy for rapid cycle bipolar disorder is an active area of research. Pharmacotherapy for rapid cycle bipolar disorder is still very relevant [15, 21,24].…”

Section: Discussionmentioning

confidence: 99%

Bats: One of the Key Animals for Humanity; A Case Study for COVID 19

Koyunoğlu¹

2020

BRCR

View full text Add to dashboard Cite

Since the protection of populations of bats, which is one of the most important creatures that provide pollination among flowers in our world, negatively affects flower pollination, the insufficiency of biocapacity in the world, that is, the decrease of the amount of conversion of carbon energy to carbonhydrate, which is the human food source of human energy, reaching the world in 2018 (1st August, according to earthovershootday.org), and the immune system, which decreases in human nutrition, which protects the balance of natüre. It is inevitable that people who die due to food shortages every year in the world as a result of an epidemic, as a result of a living creature named COVID-19 chosen to live in order to preserve the species population required for this purpose. What is certain here is that the use of the bat population for food is now a serious threat to the human species.

show abstract

“…Как было отмечено вначале, изучение возможностей фармакотерапии БАР с быстрыми циклами активно продолжается. Разработка проблемы лечения БАР с быстрыми циклами сохраняет актуальность [12][13][14].…”

Section: результаты и их обсуждениеunclassified

Simultaneous Use of Carbamazepine and Lithium in the Treatment of Outpatients with Rapid Cycle Bipolar Disorder: Randomized, Double-Blind Placebo-Controlled Study

Aliev

2021

Psychiatry

View full text Add to dashboard Cite

Purpose: rapid cycle bipolar disorder may be more resistant to treatment than other bipolar disorders. However, the effect of the synergistic use of carbamazepine and lithium in the treatment of outpatients with rapid cycle bipolar disorder without psychiatric comorbidity has not been studied in a double-blind, placebo-controlled design.Patients and methods: participants in a double-blind, placebo-controlled study met DSM-5 criteria for bipolar disorder with a rapid cycle between the ages of 18 and 65 years. The response and side effects of carbamazepine, lithium, and placebo were compared using analysis of variance (ANOVA) and chi-square tests. The respondent underwent F2, demonstrating superiority with respect to carbamazepine and lithium than in the case of placebo. Carbamazepine and lithium were generally well tolerated by the study patients, although a larger number of patients receiving carbamazepine and lithium (n = 2) early discontinued the study due to side effects.Results: twenty-seven of the 36 participants taking the combined carbamazepine and lithium regimen responded at 12 weeks, compared with six of 38 participants who received a placebo (p < 0.001). Two common side effects that led to discontinuation of carbamazepine and the lithium group were allergic reaction and drowsiness. Frequent complaints of sweating and headache during placebo treatment occurred in two out of 38 men. There were no unexpected or serious adverse events.Conclusions: the combined use of carbamazepine and lithium in the treatment of outpatients with rapid cycle bipolar disorder has demonstrated superior use of carbamazepine and lithium than placebo.

show abstract

Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder

Cited by 11 publications

References 18 publications

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies

Bats: One of the Key Animals for Humanity; A Case Study for COVID 19

Simultaneous Use of Carbamazepine and Lithium in the Treatment of Outpatients with Rapid Cycle Bipolar Disorder: Randomized, Double-Blind Placebo-Controlled Study

Contact Info

Product

Resources

About